Antibodies against eight synthetic peptides spanning different epitopes located on L1, L2, and E4 proteins of human papillomavirus (HPV) types 16,6, and 11 were examined in sera from 73 women infected by HPV and from 139 healthy controls. Only three of these peptides were reactive. Two located on pr
Occurrence of antibodies TO L1, L2, E4 and E7 gene products of human papillomavirus types 6b, 16 and 18 among cervical cancer patients and controls
✍ Scribed by Heinrich G. Köchel; Masyar Monazahian; Kai Sievert; Michaela Höhne; Christoph Thomssen; Alexander Teichmann; Peter Arendt; Reiner Thomssen
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- French
- Weight
- 820 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Sera from I 18 women of 33 to over 90 years of age, with or without a history of cervical squamous-cell carcinoma, were examined for the presence of antibodies to HPV-6b, HPV-I6 and HPV-18 LI, U, E4, and E7 gene products by the use of bacterially derived P-Gal fusion proteins and Western-blot analysis. Among the cervical cancer patients, 29/46 (63.0%) were positive for antibodies to E4 and/or E7 of HPV-I 6 and/or E7 of HPV-18. In contrast, only 2 of 31 (6.5%) non-genital cancer patients and 4 of 41 (9.8%) healthy individuals were antibody-positive for HPV-I6 E4 or E7. while antibodies to the homologous proteins of HPV-18 could not be detected. Prevalence rates of antibodies to the HPV-1611 8 late proteins were 25/46 (54.3%) in the cervical carcinoma group, 1313 I (4 I .9%) among women with non-genital cancer types, and 18/41 (43.9%) 4To whom correspondence and reprint requests should be sent.
📜 SIMILAR VOLUMES
## Abstract High‐risk human papillomaviruses (HPVs) are risk factors for the development of cervical cancer. HPV 16 is the most common type, being present in about 60% of cervical cancers worldwide. Previous studies have reported upon the association between HPV 16 E6 variants and increased risk of